CSL BEHRING LLC for CSL BEHRING LLC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Education efforts surrounding hemophilia B and a new gene therapy treatment that CSL Behring submitted to FDA, which has been licensed. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. HR 2617--Consolidated Appropriations Act 2023--Discussion of health policy riders within the legislation, including language surrounding the accelerated approval pathway and clinical trial diversity.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| MARY LACEY REUTHER | — |
Immigration IMM
Customs and Border Protection policy regarding B1/B2 visa holder eligibility to cross the US border to donate plasma.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| MARY LACEY REUTHER | — |
Taxation/Internal Revenue Code TAX
HR 2617--Consolidated Appropriations Act 2023--Sought to include language that would delay the requirement to amortize Research & Development expenses over 5 years instead of obtaining an immediate deduction from taxable income.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.